aminoglutethimide has been researched along with Ovarian Neoplasms in 3 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three sequential phase II trials were performed in patients with refractory epithelial ovarian carcinoma, using high-dose megestrol acetate (800 mg/d for 30 days, then 400 mg/d), high-dose tamoxifen (80 mg/d for 30 days, then 40 mg/d), and aminoglutethimide (1 g/d plus tapering doses of hydrocortisone)." | 5.07 | Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. ( Ahlgren, JD; Alt, D; Ellison, NM; Gottlieb, RJ; Laluna, F; Lokich, JJ; Sinclair, PR; Ueno, W; Wampler, GL; Yeung, KY, 1993) |
| " There is a tendency towards an increased response-rate with increased dosage of progestin, in both endometrial and breast carcinoma, while the route of administration appears to be of minor importance." | 2.37 | Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. ( Kauppila, A, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kauppila, A | 1 |
| Ahlgren, JD | 1 |
| Ellison, NM | 1 |
| Gottlieb, RJ | 1 |
| Laluna, F | 1 |
| Lokich, JJ | 1 |
| Sinclair, PR | 1 |
| Ueno, W | 1 |
| Wampler, GL | 1 |
| Yeung, KY | 1 |
| Alt, D | 1 |
| Eggenberger, C | 1 |
| Brändle, M | 1 |
| Galeazzi, RL | 1 |
| Spinas, GA | 1 |
| Schmid, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aminoglutethimide and Ovarian Neoplasms
| Article | Year |
|---|---|
Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bromocriptine; | 1984 |
1 trial available for aminoglutethimide and Ovarian Neoplasms
| Article | Year |
|---|---|
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
Topics: Adenocarcinoma; Aminoglutethimide; Carcinoma; Drug Resistance; Drug Therapy, Combination; Female; Hu | 1993 |
1 other study available for aminoglutethimide and Ovarian Neoplasms
| Article | Year |
|---|---|
[Cushing syndrome due to ectopic ACTH secretion: an uncommon case presentation, diagnosis and therapy].
Topics: ACTH Syndrome, Ectopic; Adenocarcinoma; Aminoglutethimide; Antineoplastic Agents, Hormonal; Diagnost | 1999 |